38.50 -0.23 (-0.59%)
After hours: 7:23PM EDT
|Bid||38.20 x 2200|
|Ask||38.93 x 1800|
|Day's Range||37.93 - 38.78|
|52 Week Range||29.39 - 47.82|
|PE Ratio (TTM)||28.60|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.86|
Let's check out the Yahoo Finance charts of the day. General Electric (GE): Shares are down in early trade, at around .68%. GE was urged by France's finance minister to stick to its commitment to create 1,000 jobs at energy producer Alstom. The company made the commitment in 2015 when it bought Alstom's energy business, but GE subsequently said the target was out of reach. Microsoft (MSFT): Shares up here, at .20%. Reuters is reporting that Microsoft is working on technology that would eliminate cashiers and checkout lines from stores. The technology would represent a challenge to Amazon's automated grocery stores. Mylan (MYL): Shares down here, at around 3.7%. U.S. health regulators were unable to approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug Advair for the second time, as they found "minor deficiencies" in the treatment. For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.
Nearly two years after taking tremendous heat for the rising cost of EpiPens, pharmaceutical giant Mylan is making strides in the fast-growing biosimilar market. Biosimilars are drugs and devices made to be similar to already-approved products, potentially lowering the cost of treatment. Mylan won FDA approval last week for a biosimilar drug designed to help some cancer patients reduce infection risk during chemotherapy. Mylan CEO Heather Bresch joins "CBS This Morning" to explain how biosimilars could translate to patient savings, what the company learned from the EpiPen debacle, and why she applauds President Trump's plan to reduce drug costs.
HERTFORDSHIRE, England and PITTSBURGH, June 18, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (MYL) today announced the U.S. launch of Bivalirudin for Injection, 250 mg single-dose vial, a generic version of Angiomax® from The Medicines Company. The product is a direct thrombin inhibitor indicated for use as an anticoagulant in patients.
Dr. Reddy's (RDY) and Mylan announced that the FDA approved the first generic version of Suboxone (Buprenorphine and Naloxone Sublingual Film) under-the-tongue film for the treatment of opioid addiction.
U.S. regulators have approved the first generic version of an under-the-tongue film for treating opioid addiction.
The Dow Jones Industrial Average finished lower today, but the other major indexes fared better. •...and explain why Twitter (TWTR) soared. The S&P 500 has come to a standstill, but don't expect it to stay that way for long.
The U.S. Food and Drug Administration late Thursday said it approved the first generic version of a Suboxone under-the-tongue film for the treatment of opioid addiction. Mylan Technologies Inc., a subsidiary ...
On June 13, Mylan (MYL) announced that the FDA didn’t approve its generic version of GlaxoSmithKline’s (GSK) Advair Diskus, an asthma drug and inhaler combination. The FDA cited “minor deficiencies” in Mylan’s ANDA (abbreviated new drug application) for its generic Advair, which was first dismissed by the FDA in March 2017.
Investors didn't cut Mylan any slack Thursday after the company announced U.S. regulators would likely delay its generic version of blockbuster asthma inhaler Advair.
U.S. stocks rose on Thursday after the European Central Bank promised not to raise euro zone interest rates before the middle of next year and on better-than-expected May retail sales data. The bank's statement came as a relief, especially after the U.S. Federal Reserve raised interest rates for the second time this year on Wednesday and hinted at two more hikes by the end of 2018.
Mylan and Oracle dragged on early trade, but positive news out of Europe sent futures higher, and IPOs Etsy, Huya and Pivotal were poised to nail news highs.
Wall Street was on track to open higher on Thursday after strong retail sales data, while investors assessed the European Central Bank's move to end its stimulus program and the Federal Reserve's guidance on monetary policy. The Fed raised its benchmark interest rates by 25 basis points for the second time this year on Wednesday and hinted at two more hikes by the end of 2018.
Check out the companies making headlines after the bell on Wednesday: Shares of Tailored Brands TLRD plummeted nearly 20 percent after the bell, despite reporting first-quarter earnings and revenue that beat analysts' expectations.
Pounded. Mylan NV said Wednesday, June 13, that the U.S. Food and Drug Administration "has identified minor deficiencies" that the agency will relay in a letter later this month regarding Mylan's application for a generic version of GlaxoSmithKline plc's asthma drug Advair.
Mylan NV said on Wednesday that U.S. health regulators were unable to approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug Advair for the second time, as they found "minor deficiencies" in the treatment. Shares of Mylan fell 4.5 percent to $39.80 after the bell. Mylan did not provide details on the nature of the deficiencies cited by the U.S. Food And Drug Administration and it remains unclear whether the company will be able to resolve them and get approval this year.
Mylan shares plunged late Wednesday after the FDA identified "minor deficiencies" in its application for a generic copy of GlaxoSmithKline's drug Advair.
NEW YORK, June 12, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Regency ...
It's been nearly two years since the pharmaceutical giant took tremendous heat for the rising cost of EpiPens